AMO Pharma Announces Affirming Data from REACH-CDM Clinical Trial for AMO-02 in Treatment of Myotonic Dystrophy

AMO Pharma Limited ("AMO Pharma"), a privately held clinical-stage specialty biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, today announced results from the company's REACH-CDM clinical study of the investigational therapy AMO-02 in the treatment of children and adolescents with congenital myotonic dystrophy. 

Read full article.